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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of n3 polyunsaturated fatty acids (n3PUFAs) (also known as omega-3 fatty acids) compared with comparator (e.g.
placebo, anti-depressant treatment, standard care, no treatment, wait-list control) for major depressive disorder in adults.
B A C K G R O U N D
Description of the condition
Major depressive disorder (MDD) is characterised by: depressed
mood; markedly diminished pleasure or interest in all activities;
significant weight loss or weight gain, or decrease or increase in
appetite; insomnia or hypersomnia; psychomotor agitation or re-
tardation; fatigue or lethargy; feelings of worthlessness or inap-
propriate guilt; disruptions to concentration and decision-mak-
ing; and recurrent thoughts of death (APA 2013). Diagnosis is
achieved by: the presence of four or more symptoms (as above)
plus depressed mood or markedly diminished pleasure or interest
in all activities, for a consecutive period of two weeks; significant
distress or impairment in functioning as a result of the symptoms;
and an inability to attribute symptoms to the physiological effects
of a substance or another medical condition (APA 2013). MDD
is currently estimated to affect approximately 7% of western pop-
ulations, with resulting impact both at an individual and a societal
level (APA 2013). MDD can be highly debilitating; affect all areas
of an individual’s life; can be difficult to treat, with a high rate of
recurrence; and often exists in combination with other conditions
and disorders, such as cardiovascular disease and anxiety disorders
(APA 2013). Recent figures (2011) by the World Health Organi-
zation estimate major depressive disorders to account for 3% of
global ill health in terms of disability-adjusted life years (WHO
2014), and projections for 2030 suggest an increase to 6% to 7%
(WHO2014). Given this increasing trend, there is an urgent need
for effective treatments and strategies for prevention.
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Description of the intervention
One emerging potential treatment forMDD exists in the family of
n3 polyunsaturated fatty acids (n3PUFAs), also known as omega-
3 fatty acids.
n3PUFAs are a family of polyunsaturated fatty acids, named as
such due to the positioning of the first double carbon bond on the
third atom from the methyl end of the acyl chain. All members of
the family are derived from the parent fatty acid 18:3n3 (Alpha-
linolenic Acid (ALA)), via desaturation and elongation. ALA how-
ever can not be synthesised by humans, and thus must be obtained
from the diet (Haag 2003; Ruxton 2005). Longer chain n3PUFAs
can be formed in humans, but biological conversion is slow and
inefficient, making diet an important source for these fatty acids
as well (Ma 1995). Dietary sources of ALA include certain nuts
and seeds, such as walnuts, flaxseed and rapeseed (canola) oil. Di-
etary sources of the longer n3PUFAs eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) include fatty fish, some white
fish, shellfish and other seafood such as seaweed, and certain eggs
and animal products dependent on the animal’s diet (BNF 1999;
James 2000; Ruxton 2005; Simopolous 1999).
Links between n3PUFAs andMDDwere first suggested following
recognition of a drastic reduction in the dietary consumption of
n3PUFAs in recent decades (Simopolous 1999).Coupledwith this
reduction in n3PUFA intakes, intakes of n6 long chain polyunsat-
urated fatty acids (n6PUFAs) have considerably increased. Closely
related to the n3PUFAs, n6PUFAs (named from the positioning
of the first double bond on the sixth carbon atom from the methyl
end of the acyl chain) are derived from the parent essential fatty
acid 18:2n6 (Linoleic Acid (LA)), and for synthesis, share the same
desaturases and elongases as n3PUFAs. N3PUFAs and n6PUFAs
thus compete for synthesis from their parent fatty acids. Dietary
sources of LA and all n6PUFAs include plant and vegetable seeds
and oils, as found in margarines and the majority of processed
foods (James 2000; Simopolous 1999). Our traditional diet is
thought to have contained approximately equal amounts of energy
from n3PUFAs and n6PUFAs (Simopolous 1999). By compari-
son, a current western diet is estimated to contain approximately
5 to 20 times more energy from n6PUFAs than from n3PUFAs
(Gregory 2000; Simopolous 1999).
Early work investigating population consumption levels of
n3PUFAs and n3PUFA rich foods, such as fish, suggest clear links
with population levels of MDD and other psychiatric conditions
(Hibbeln 1998; Noaghiul 2003; Peet 2004), and repeated stud-
ies since have also found similar associations. Within countries,
n3PUFA intakes have been negatively associated with depressive
illness (e.g. Silvers 2002; Tanskanen 2001). In clinical studies, low
levels of n3PUFAs have been found in individuals diagnosed with
MDD (e.g. Edwards 1998; Peet 1998) and depressive disorders
(e.g. Garland 2007), and reporting high levels of depressed mood
(e.g. Mamalakis 2002; Mamalakis 2006) compared to controls.
Continuous relationships between n3PUFA status and depressive
symptoms have also been found (e.g. Edwards 1998). In ran-
domised controlled trials (RCTs), beneficial effects of supplemen-
tation with n3PUFAs compared to placebo have been reported for
MDD (e.g. Nemets 2002; Su 2003) and depressive disorders (e.g.
Frangou 2006; Stoll 1999).
How the intervention might work
The positive effects of n3PUFAs on depressive illness are thought
to occur as a result of changes to cell membrane structure and func-
tion, impacting particularly on cell communication, inflamma-
tory processes and neurotransmitter activities (Haag 2003; James
2000; Ruxton 2005). Further details are available in Appendix 1.
Disruptions to and abnormal cell signalling, inflammatory pro-
cesses and neurotransmitter system activities have been implicated
in MDD (Parker 2006; Stahl 2008).
Why it is important to do this review
N3PUFAs are known to be important in brain development and
function, and have been linked to depression in a variety of studies,
see Appendix 2. Not all studies, however, report beneficial effects
(see Appendix 2), and reviews and meta-analyses clearly demon-
strate considerable variability between studies (e.g. Appleton 2006;
Appleton 2008b; Appleton 2010; Lin 2007; Parker 2006; Smith
2011; Stahl 2008). Meta-analyses reveal some small benefit of
n3PUFAs for depressive disorders (Appleton 2006; Lin 2007),
but investigations of the considerable heterogeneity also suggest
differential effects of n3PUFAs, dependent primarily on severity
of depressive symptoms at baseline (Appleton 2010). Sensitivity
analyses based on severity of depressive symptoms at baseline sug-
gest no benefits of n3PUFAs for individuals with mild depressive
symptoms or without diagnosis of depression, but also provide
some evidence of benefits in individuals with severe depressive
symptoms or with depressive diagnoses (Appleton 2010). These
findings suggest a possible benefit of n3PUFAs for MDD. This
review will investigate a role of n3PUFAs as a treatment forMDD.
Various reviews of other treatments forMDD and other depressive
disorders are available. A recent search of The Cochrane Library
revealed 98 completed reviews or reviews in progress focusing on
treating or preventing depression. The majority of these reviews
investigate pharmacological (e.g. antidepressant) or psychological
(e.g. cognitive behavioural therapy) therapies for depressive con-
ditions, or focus on specific clinical populations, e.g. stroke pa-
tients or patients with diabetes mellitus. Only two of these reviews
include n3PUFAs, both focussing on antenatal and postnatal de-
pression.One review investigates ’dietary supplements for prevent-
ing postnatal depression’ (Miller 2013), and includes one study
of n3PUFAs. This study found no significant preventive impact
of n3PUFAs on the presence of postnatal depression. The other
review (Dennis 2013) includes two trials investigating the use of
n3PUFAs for antenatal depression, and reports a beneficial effect
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on depression in one trial and no benefits in the other. One fur-
ther review also focuses on a herbal treatment (St John’s Wort) for
depression (Linde 2008), but the active component of this plant-
based treatment is unrelated to n3PUFAs or other fatty acids.
O B J E C T I V E S
To assess the effects of n3 polyunsaturated fatty acids (n3PUFAs)
(also known as omega-3 fatty acids) compared with comparator
(e.g. placebo, anti-depressant treatment, standard care, no treat-
ment, wait-list control) for major depressive disorder in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCTs) will be included, as the
best study design for assessing an intervention. All RCTs will be
included regardless of quality, but measures of risk of bias will be
recorded. We will exclude observational and case-control studies.
We will include cross-over RCTS, although only the first study
phase of cross-over trials will be used in analyses, to avoid carry-
over effects.
Cluster RCTs will be included in primary analyses, where the
cluster will act as the unit of investigation. We think cluster and
especially cross-over RCTs are unlikely to be used in this field.
Our aim is to include as many relevant studies as possible to avoid
limitations and bias, while recording possible confounding and
investigating this where numbers allow.
Types of participants
Participant characteristics
Studies will be included regardless of participant demographics
(e.g. gender, age, country of residence), although only studies in-
volving adults (18 years and over) will be included.
Diagnosis
Wewill only include studies that enrolled participants with a diag-
nosis of major or unipolar depressive disorder from a trained pro-
fessional or using a validated rating scale, or studies that include a
subgroup of these individuals. If a subgroup is used, only the data
from the subgroup will be included in the review. If data from
diagnosed and non-diagnosed individuals are mixed, these studies
and these data will not be included. Studies that enrolled partici-
pants without MDD, but with an alternative depressive disorder,
e.g. bipolar disorder, postpartum depression (APA 2013) will not
be included. We will exclude studies that describe a diagnosis of
MDD that is given only during or in relation to pregnancy.
Studieswill be included regardless of participantmedication. Stud-
ies involving participants with concomitant medication will be in-
cluded due to the high likelihood of use in the MDD population
(APA 2013), and a desire to make the review as generalisable as
possible. Medication will be recorded as part of the review and
investigated in subgroup analyses if possible.
Comorbidities
We will include studies regardless of the use of participants with
other comorbid conditions (physical conditions, e.g. CHDor psy-
chiatric conditions, e.g. anxiety). Studies involving participants
with comorbid conditions will be included due to the high like-
lihood of existing comorbidities in the MDD population (APA
2013), and a desire to make the review as generalisable as possi-
ble. Investigation of effects due to existing comorbidities will be
undertaken in subgroup analyses, where possible dependent on
available data.
Setting
Studies will be included regardless of setting, provided a clinical
diagnosis has been provided.
Types of interventions
Experimental intervention
Studies will be included if they use an exposure of n3PUFAs as
a sole or adjunctive therapy. Studies will be included regardless
of: the source of n3PUFA provided (pure ALA, EPA, DHA or
any combination of these, fish, flaxseed, rapeseed, etc); the dose of
n3PUFA or duration of supplementation; and the mode of provi-
sion (i.e. supplement capsules, supplemented foods), but records
of these differences will be made. Studies will be included in the
main review if details of type of n3PUFA, dose, and ratio are not
available, as mechanisms for action remain unknown. Studies with
a ’lead-in’ phase to allow for spontaneous remission or placebo
responding in participants will be included, and use of the ’lead
in’ phase will be recorded.
Comparator intervention
Studies will be included regardless of the comparator used, but a
comparator must be used and all comparators will be recorded,
and investigated if possible. Wait-list controls, no treatment or
3Omega-3 fatty acids for depression in adults (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
standard care will be included as comparators. Studies will be in-
cluded regardless of participant medication. Studies involving par-
ticipants with concomitant medication will be included due to the
high likelihood of use in theMDD population (APA 2013), and a
desire to make the review as generalisable as possible. Medication
will be recorded as part of the review and investigated in subgroup
analyses if possible.
Types of outcome measures
We will include studies that meet the above criteria, regardless of
whether they report on all of the following outcomes.
Primary outcomes
1.Depressive symptomology (continuous data) -Depressive symp-
tomology will be assessed using any continuous validated mea-
sure of depressive symptomology. The most commonly used vali-
dated rating scales are the BeckDepression Inventory (Beck 1987),
the Montgomery-Asberg Depression Rating Scale (Montgomery
1979), and theHamiltonDepression Index (Hamilton 1960), but
studies using other scales will also be included.
2. Adverse events - Measures of adverse events will be recorded if
possible. Number and type (e.g. gastrointestinal, psychiatric) of
adverse events experienced will be recorded as reported in studies.
Number of individuals suffering, as opposed to number of events,
will be used in analyses. Where adverse events are not reported,
this will be recorded.
Secondary outcomes
3. Depressive symptomology (dichotomous data) - Depressive
symptomology will also be assessed using remission or improve-
ment as assessed using clinical diagnoses by a trained professional
or a validated rating scale, where provided.
4. Quality of life (continuous data) - Quality of life will be assessed
using any continuous validated measure of quality of life.
5. Failure to complete - Number of individuals leaving each study
early, and reasons for early drop-out will be recorded.
Timing of outcome assessment
Where studies use multiple time points, data from the longest fol-
low-up period only will be used for analysis. Data will be tabu-
lated for all outcomes at all time points where assessments have
been made, but only those of longest follow-up will be included
in statistical analyses. Previous work suggests that effects are likely
to increase over time (Calder 2003; Ruxton 2005).
Search methods for identification of studies
Suitable studies for inclusion will be identified by searching
databases, international trials registers and published review arti-
cles, and by contacting authors of published trials.
Electronic searches
The Cochrane Depression, Anxiety and Neurosis Review
Group’s Specialised Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN)maintain two clinical trials registers at their editorial base in
Bristol, UK: a references register and a studies based register. The
CCDANCTR-References Register contains over 31,500 reports
of RCTs in depression, anxiety and neurosis. Approximately 65%
of these references have been tagged to individual, coded trials.
The coded trials are held in the CCDANCTR-Studies Register
and records are linked between the two registers through the use
of unique Study ID tags. Coding of trials is based on the EU-Psi
coding manual, using a controlled vocabulary (please contact the
CCDAN Trials Search Coordinator for further details). Reports
of trials for inclusion in the Group’s registers are collated from
routine (weekly), generic searches of MEDLINE (1950-), EM-
BASE (1974-) and PsycINFO (1967-); quarterly searches of the
Cochrane Central Register of Controlled Trials (CENTRAL) and
review specific searches of additional databases. Reports of trials
are also sourced from international trials registers c/o the World
Health Organization’s trials portal (the International Clinical Tri-
als Registry Platform (ICTRP)), pharmaceutical companies, the
handsearching of key journals, conference proceedings and other
(non-Cochrane) systematic reviews and meta-analyses.
Details of CCDAN’s generic search strategies (used to identify
RCTs) can be found on the Group’s website.
1. The CCDANCTR (Studies and References Registers) will be
searched using the following terms:
(depress* or dysthymi* or “affective disorder*” or “affective symptom*”
or “mood disorder*” or “mental health”) AND (dha or docosahex* or
eicosapent* or epa or “fatty acid*” or *fish* or *linolenic* or *omega*
or n-3 or w-3 or *PUFA* or “cod liver oil”)
2. Complementary searches will be conducted on the following
bibliographic databases using relevant subject headings (controlled
vocabularies) and search syntax, appropriate to each resource:
• CINAHL (Cumulative Index to Nursing & Allied Health)
(1982 to date), search strategy listed in Appendix 3
• BIOSIS Citation Index (1969 to date)
• Web of Science (1900 to date)
Therewill be no restrictions ondate, language or publication status
applied to the searches.
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3. International trial registries will be searched via the World
HealthOrganization’s trials portal (ICTRP) and ClinicalTrials.gov
to identify unpublished or ongoing studies.
Searching other resources
Wewill check the reference lists of all included studies and relevant
systematic reviews to identify additional studies missed from the
original electronic searches.
We will contact authors of relevant publications (reports of in-
cluded studies) and principle investigators of currently registered
trials for information on unpublished or ongoing studies or to
request additional trial data.
Data collection and analysis
Wewill download search results into Endnote. Selected studies will
be downloaded into RevMan (RevMan 2012). We will provide
details of all work undertaken and number of potentially-eligible
studies at all steps of the search and selection process.
Selection of studies
Two review authors (RP, HS) will independently screen for inclu-
sion the titles and abstracts of all the studies we identify as a result
of the search, and code them as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. We will retrieve the poten-
tially-relevant full-text study reports/publication and two review
authors (RP, HS) will independently screen the full-text and iden-
tify studies for inclusion, and identify and record reasons for ex-
clusion of the ineligible studies. We will resolve any disagreement
through discussion or, if required, we will consult a third person
(KA). We will identify and exclude duplicate records, and we will
collate multiple reports that relate to the same study, so that each
study rather than each report is the unit of interest in the review.
Titles or abstracts which may be relevant, but where relevance is
not clear, will be included in the list and obtained. Articles in for-
eign languages will be obtained and translated where necessary, as
may be the case, particularly for unpublished or preliminary data.
We will record the selection process in sufficient detail to complete
a PRISMA flow diagram and ’Characteristics of excluded studies’
table.
Data extraction and management
We will use a data collection form, developed specifically for this
work, to extract study characteristics and outcome data, which
has been piloted on at least one study in the review. Two review
authors (HS and KA or RP) will extract study characteristics and
outcome data from included studies. We will extract the following
study characteristics.
1. Methods: study design, total duration of study, details of
any ’lead in’ period, use of several study centres, study location,
study setting, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, inclusion criteria, and exclusion
criteria, withdrawals.
3. Interventions: intervention, comparator, concomitant
medications, and comorbidities.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Where multiple reports of the same study are available, data will
be abstracted from all reports on separate data extraction forms
and subsequently combined. Discordances will be resolved by in-
dependent abstraction and then discussion with a third author.
Where data are unavailable as required, corresponding authors will
be contacted directly for relevant information.
We will note in the ’Characteristics of included studies’ table if
outcome data were not reported in a usable way. We will resolve
disagreements by consensus or by involving a third person (RC,
AN). Two review authors (RP, HS) will transfer data into the
Review Manager (RevMan 2012) file. We will double-check that
data are entered correctly by comparing the data presented in the
systematic review with the study reports. A second review author
(KA) will spot-check study characteristics for accuracy against the
trial report.
Main comparisons
• n3PUFAs versus comparator. We will conduct analyses by
comparator type.
Assessment of risk of bias in included studies
Three review authors (KA, RP, HS) will independently assess the
risk of bias for each study using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (RC, AN). We will assess the risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will judge each potential source of bias as high, low or unclear
risk and provide a supporting quotation from the study report
together with a justification for our judgment in the ’Risk of bias’
table. We will summarise the risk of bias judgements across differ-
ent studies for each of the domains listed. Where information on
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risk of bias relates to unpublished data or correspondence with a
triallist, we will note this in the ’Risk of bias’ table. When consid-
ering treatment effects, we will take into account the risk of bias
for the studies that contribute to that outcome.
Measures of treatment effect
Dichotomous data
Depressive diagnosis or status will be recorded as provided. Di-
chotomous data will be collected in the form of N with diagnosis
per intervention group. We will analyse dichotomous data as odds
ratios (OR) with 95% confidence intervals (CI).
Continuous data
Depressive symptomology andquality of life will be recordedusing
all scales as used in each study, after ensuring comparable direction.
Analyses will be conducted on data from only one scale per study.
For depressive symptomology, we will use either the scale most
commonly used in all studies, or the Beck Depression Inventory
(Beck 1987) as the most respected of depression scales validated
in depressive populations. For quality of life, we will use the scale
most commonly used in all studies reporting quality of life.
Continuous data will be collected in the form of N, mean, and
standard deviation, per intervention group at baseline and at the
end of each intervention, as required for meta-analysis. If data are
only provided in other forms, e.g. as medians, change from base-
line, we will contact study authors and request appropriate data.
Data from subgroups of little relevance to the research question,
e.g. groups of males and females, will be recorded as reported, and
subsequently combined for analysis.
We will analyse continuous data as mean difference (MD) with
95% CI or standardised mean difference (SMD) with 95% CI.
We will enter data presented as a scale with a consistent direc-
tion of effect. We will undertake meta-analyses only where this is
meaningful, i.e. if the treatments, participants and the underlying
clinical question are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and
interquartile ranges. Where multiple trial arms are reported in a
single trial, we will include only the relevant arms.
Data on adverse events will be reported by number of individuals
suffering as opposed to number of events.
Data on failure to complete will be reported as number of indi-
viduals failing to complete each trial, and reasons given for non-
completion.
Unit of analysis issues
Cross-over RCTs
Only the first study phase of cross-over RCTs will be included in
analyses. We think cross-over RCTs are unlikely to be used in this
field.
Cluster RCTs
Cluster RCTs will be included in primary analyses, where the
cluster will act as the unit of investigation. We think cluster RCTs
are unlikely to be used in this field.
Studies with multiple treatment groups
Where studies use multiple treatment groups, each treatment
group will be treated independently and included in all appropri-
ate analyses. In these cases, the same comparator will be used for
all treatment groups. Assuming individuals took part in only one
treatment/comparator group, groups are independent. Data from
comparison groups will be split across treatment groups for anal-
ysis. Studies where individuals are provided with multiple treat-
ments will be considered as cross-over RCTs; however we think
these sorts of studies are very unlikely to be used.
Dealing with missing data
We will contact investigators in order to verify key study charac-
teristics and obtain missing numerical outcome data where possi-
ble (e.g. when a study is identified as abstract only). We will doc-
ument all correspondence with trialists and report which trialists
responded in the full review.
Standard deviations which remain missing once authors have been
contacted will be imputed from standard deviation data from all
other trials using the same measure for depression in the review
(Furukawa 2006).
Assessment of heterogeneity
Heterogeneity will be investigated using Higgins’ I2 statistic
(Higgins 2002; Higgins 2004). I2 statistics and appropriate P val-
ueswill be reported. Four bands of the I2 statisticwill be used for in-
terpretation, as recommended in theCochrane Handbook (Higgins
2011). These bands are 0% to 40%: might not be important;
30% to 60%: may representmoderate heterogeneity; 50% to 90%
may represent substantial heterogeneity; and 75% to 100%: con-
siderable heterogeneity. Possible sources of heterogeneity will be
identified a priori, to include publication bias, comparator used,
use of n3PUFAs as a sole or adjunct therapy, presence/absence of
comorbid conditions (physical and psychiatric), and risk of bias.
Publication bias will be investigated using funnel plot asymme-
try (Sterne 2001). Investigations of heterogeneity and sensitivity
analyses on possible sources of heterogeneity will be conducted if
possible. We suspect these investigations may be limited by the
small number of studies likely to be identified.
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Assessment of reporting biases
Publication bias will be investigated using funnel plot asymmetry
(Sterne 2001). This will only be undertaken if there are more than
10 studies available. It should be noted that publication bias is one
of several possible causes of asymmetry in funnel plots.
Data synthesis
Data from trials reporting mean and standard deviation data will
be combined using meta-analysis (Sterne 2001). Analyses will be
conducted twice: once using only studies at low risk of bias, and
once using all included studies. Intention-to-treat (ITT) data will
be used, where possible, andwill be sought if not publicly available.
If ITT data cannot be obtained, we will use available data.
For continuous data, the standardised mean effect for all trials will
be calculated using Hedges’ adjusted g (Deeks 2001). Hedges’ ad-
justed g is a formulation of effect size used in the SMD method
that includes an adjustment to correct for small sample bias (Deeks
2001). Studieswill beweighted using the inverse-variancemethod.
Random-effects models will be used primarily to estimate the
SMDs for all analyses (Deeks 2001; Egger 2001; Sterne 2001).
Fixed-effect models will also be applied as sensitivity analyses. Ef-
fect sizes will be provided as means and standard deviations, and
related to specific scales to allow understanding by clinicians and
practitioners.
For dichotomous data, we will use the Mantel-Haenszel method.
Adverse effects and failure to complete data will not be statistically
summarised.
If data from a single study cannot be included in a statistical com-
bination, this will be reported and outcomes of that single study
will be reported separately.
Subgroup analysis and investigation of heterogeneity
We will conduct subgroup analyses investigating effects of
n3PUFAs on MDD in:
1. individuals with comorbid conditions versus those without.
This analysis will demonstrate effects due to participant
characteristics which may affect treatment recommendations and
outcomes. Separate analyses will be conducted using the same
methods as for the main analyses, using only studies in which
participants are clearly identified as having comorbid conditions,
and using only studies in which participants are clearly identified
as being without comorbid conditions. Studies where
participants with and without comorbid conditions are mixed,
and studies that do not clearly identify whether participants have
comorbid conditions or not, will not be included in this analysis.
Caution should be exercised in interpreting these analyses due to
the increased bias in selective samples;
2. individuals receiving medications versus those without.
This analysis will demonstrate effects due to participant
characteristics which may affect treatment recommendations and
outcomes. Separate analyses will be conducted using the same
methods as for the main analyses, using only studies in which
participants are clearly identified as receiving medication or
adjunct therapy, and using only studies in which participants are
clearly identified as not receiving medication or other adjunct
therapy. Studies where participants with additional medications
and therapies are mixed, and studies that do not clearly identify
whether or not participants were receiving additional medication
or therapies, will not be included in this analysis. Caution should
be exercised in interpreting these analyses due to the increased
bias in selective samples.
Sensitivity analysis
We will conduct sensitivity analyses to investigate the impact of:
1. including all studies versus only studies that are at low risk
of bias. This will demonstrate the importance of the use of only
those trials at low risk of bias, and the levels of confidence and
caution that should be exercised in considering the analyses on
all studies. Separate analyses will be conducted using the same
methods as for the main analyses, using all studies, and using
only the studies that are identified as being at low risk of bias.
Low risk of bias will be defined as in the Cochrane Handbook
(Higgins 2011);
2. using fixed-effect models as opposed to random-effects
models. Random-effects models will be used for all main
analyses. Fixed-effect analyses will be conducted using the same
methods as for the main analyses.
’Summary of findings’ table
Wewill provide a ’Summary of findings’ table, as recommended in
The Cochrane Handbook (Higgins 2011). Outcomes will include
depressive symptomology andmeasures of adverse events. The pri-
mary comparison will be n3PUFAs versus comparator. The qual-
ity of evidence for all outcomes will be assessed using the GRADE
system, as described by the Grades of Recommendation, Assess-
ment, Development and Evaluation Working Group. This will
involve consideration of within-study risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias.
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A P P E N D I C E S
Appendix 1. How the intervention might work
The positive effects of n3PUFAs on depressive illness are thought to occur as a result of integration into the cell membrane phospholipid
bilayer, resulting in changes in structure and function (Haag 2003; James 2000; Ruxton 2005). Incorporation into the cell membrane
can influence the physical state of the membrane, resulting in increased fluidity and permeability (Ehringer 1990; Hirashima 2004;
Tappia 1997), possibly aiding cross-cell membrane transport and communication (Haag 2003). Secondly, n3PUFAs are also thought
to have effects on surrounding molecules and cell functions via enzyme activity which results in the release of fatty acids from the
phospholipid bilayer to form a number of anti-inflammatory eicosanoids, prostaglandins, and leukotrienes (Calder 2003; James 2000;
Ruxton 2005; Stahl 2008), and via enzyme activity of direct involvement in various neurotransmitter pathways (Haag 2003; James 2000;
Ruxton 2005; Stahl 2008). Supplementation with n3PUFAs has been found to result in: reduced production of inflammatory cytokines
- tumor necrosis factor alpha (TNFa), interleukin 1B, interleukin-6, C-reactive protein and serum amyloid A (Calder 2003; Caughey
1996; James 2000; Rallidis 2003); increased serotonergic and dopaminergic activity; and decreased concentrations of noradrenalin
(Chalon 2006; de la Presa Owens 1999; Hamazaki 2005; Sawazaki 1999; Yao 2004). Additionally, n3PUFA-deficient diets have been
associated with reduced receptor density and disruptions to neurotransmitter activity in serotonergic (de la Presa Owens 1999; Delion
1994; Delion 1996; McNamara 2006), dopaminergic (Chalon 2006; de la Presa Owens 1999; Delion 1994; Delion 1996; McNamara
2006; Takeuchi 2002), and adrenergic systems (Takeuchi 2002) compared to controls. Disruptions to and abnormal cell signalling,
inflammatory processes and neurotransmitter system activities have been implicated in MDD (Parker 2006; Stahl 2008).
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Appendix 2. Why it is important to do this review
N3PUFAs have been linked to depression in a variety of epidemiological studies (Hibbeln 1998; Noaghiul 2003; Peet 2004; Silvers
2002; Tanskanen 2001); clinical studies (Edwards 1998; Garland 2007; Mamalakis 2002; Mamalakis 2006; Peet 1998); and RCTs
(Frangou 2006; Nemets 2002; Stoll 1999; Su 2003).
However, several epidemiological studies have found no association between n3PUFA intake and depressive illness (e.g. Appleton 2007;
Frangou 2006; Hakkarainen 2004; Miyake 2006; Stoll 1999; Su 2003). Clinical studies have reported no differences in n3PUFA levels
between individuals diagnosed with MDD and controls (e.g. Browne 2006; Mamalakis 2004) and no clear associations (Appleton
2008a). Several RCTs have also reported no effects of supplementation on MDD (e.g. Grenyer 2007; Silvers 2005), depressive illness
(e.g. Keck 2006) or depressed mood (e.g. Rogers 2008).
Reviews in this area clearly demonstrate considerable variability between studies (e.g. Appleton 2006; Appleton 2008b; Appleton 2010;
Lin 2007; Parker 2006; Smith 2011; Stahl 2008). Meta-analyses also report considerable heterogeneity between studies ( Appleton
2006; Appleton 2010; Lin 2007). Meta-analyses reveal some small benefit of n3PUFAs for depressive disorders (Appleton 2006; Lin
2007), but investigations of the considerable heterogeneity also suggest differential effects of n3PUFAs dependent primarily on severity
of depressive symptoms at baseline (Appleton 2010). Sensitivity analyses based on severity of depressive symptoms at baseline suggest
no benefits of n3PUFAs for individuals with mild depressive symptoms or without diagnosis of depression, but also provide some
evidence of benefits in individuals with severe depressive symptoms or with depressive diagnoses (Appleton 2010). These findings
suggest a possible benefit of n3PUFAs for MDD.
Appendix 3. CINAHL search strategy
[Diagnosis]
S1 (MH “Depression”)
S2 (MH “Depression, Reactive”)
S3 (MH “Dysthymic Disorder”)
S4 (MH “Affective Disorders”)
S5 (MH “Affective Symptoms”)
S6 (depress* or dysthymi* or “adjustment disorder*” or “affective disorder*” or “affective symptom*” or “mood disorder*”)
S7 (S1 or S2 or S3 or S4 or S5 or S6 or S7)
[Intervention]
S8 (MH “FISH OILS”)
S9 (MH “FATTY ACIDS, OMEGA-3”)
S10 (MH “DOCOSAHEXAENOIC ACIDS”)
S11 (MH “EICOSAPENTAENOIC ACID”)
S12 (AB ( (DHA or Docosahex* or Eicosapent* or EPA or “fatty acid*” or fish* or linolenic or omega-3 or n-3 or w-3 or PUFA* or
“cod liver oil” or “cod-liver oil”) ) OR TI ( (DHA or Docosahex* or Eicosapent* or EPA or “fatty acid*” or fish* or linolenic or omega-
3 or n-3 or w-3 or PUFA* or “cod liver oil” or “cod-liver oil”)))
S13 (S8 or S9 or S10 or S11 or s12)
[RCT Filter]
S14 (MH “Clinical Trials+”)
S15 (PT Clinical trial)
S16 (TX clini* N3 (trial* or study or studies))
S17 (TX ((singl* N1 blind*) or (singl* N1 mask*)) or TX ((doubl* N1 blind*) or (doubl* N1 mask*))
or TX ((tripl* N1 blind*) or (tripl* N1 mask*)))
S18 (TX random* N3 control*)
S19 (MH “Random Assignment”)
S20 (TX random and (allocat* or assign*))
S21 (TX placebo*)
S22 (TX (waitlist* or (wait* and list*)) and (control* or group))
S23 (TX “treatment as usual” or TI TAU or AB TAU)
S24 (TX (control* N3 (trial* or study or studies or group*)))
S25 (MH “Quantitative Studies”)
S26 (S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25)
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S27 (S7 and S13 and s26)
WH A T ’ S N E W
Date Event Description
1 May 2014 New citation required and major changes This protocol replaces the withdrawn protocol Silvers 2009 (withdrawn).
C O N T R I B U T I O N S O F A U T H O R S
KA wrote the protocol. All authors checked and subsequently revised this draft.
D E C L A R A T I O N S O F I N T E R E S T
KA - None
RP - None
RC - None
AN - None
HS - None
S O U R C E S O F S U P P O R T
Internal sources
• Bournemouth University, UK.
Researcher time
• University of Bristol, UK.
Researcher time
External sources
• No sources of support supplied
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